“None of this had to happen. Skipping a key phase of research and performing a futility analysis weren’t scientific decisions; they were business decisions about the pace of research to discover an effective Alzheimer’s treatment and how much a company will spend to sustain that pace.”
This was in reference to skipping phase 2.
Sounds like Biogen was in a hurry to get something approved before Anavex2-73 gets approved.
News 
Market Data 
Discover 
